Cerus Corporation

6.24+0.1700+2.80%Vol 823.62K1Y Perf 19.88%
Apr 13th, 2021 14:30 DELAYED
BID6.24 ASK6.25
Open6.08 Previous Close6.07
Pre-Market6.09 After-Market-
 0.02 0.33%  - -
Target Price
9.10 
Analyst Rating
Strong Buy 1.00
Potential %
47.25 
Finscreener Ranking
★★★     50.58
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     45.41
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★     47.74
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap1.05B 
Earnings Rating
Buy
Price Range Ratio 52W %
34.25 
Earnings Date
4th May 2021

Today's Price Range

6.056.25

52W Range

4.878.87

5 Year PE Ratio Range

-8.40-7.60

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Sell
Performance
1 Week
-0.16%
1 Month
-5.01%
3 Months
-18.41%
6 Months
-9.67%
1 Year
19.88%
3 Years
12.83%
5 Years
-2.41%
10 Years
125.65%

TickerPriceChg.Chg.%
CERS6.240.17002.80
AAPL134.273.03002.31
GOOG2 262.307.51000.33
MSFT257.841.93000.75
XOM55.630.13000.23
WFC39.81-0.9600-2.35
JNJ159.11-2.5300-1.57
FB312.160.62000.20
GE13.49-0.1000-0.74
JPM154.41-1.5400-0.99
Financial StrengthValueIndustryS&P 500US Markets
2.60
3.10
0.35
0.64
-14.90
Leverage Ratio 2.00
ProfitabilityValueIndustryS&P 500US Markets
55.20
-48.90
-46.10
-94.70
-47.86
RevenueValueIndustryS&P 500US Markets
89.61M
0.53
23.94
29.47
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.08-0.09-12.50
Q03 2020-0.12-0.0833.33
Q02 2020-0.10-0.0910.00
Q01 2020-0.10-0.100.00
Q04 2019-0.11-0.12-9.09
Q03 2019-0.11-0.13-18.18
Q02 2019-0.12-0.13-8.33
Q01 2019-0.12-0.14-16.67
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.0970.00Positive
6/2021 QR-0.0873.33Positive
12/2021 FY-0.33--
12/2022 FY-0.32--
Next Report Date4th May 2021
Estimated EPS Next Report-0.09
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume823.62K
Shares Outstanding168.22M
Trades Count6.00K
Dollar Volume24.89M
Avg. Volume2.22M
Avg. Weekly Volume1.28M
Avg. Monthly Volume2.19M
Avg. Quarterly Volume2.26M

Cerus Corporation (NASDAQ: CERS) stock closed at 6.07 per share at the end of the most recent trading day (a -0.98% change compared to the prior day closing price) with a volume of 916.57K shares and market capitalization of 1.05B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 270 people. Cerus Corporation CEO is William M. Greenman.

The one-year performance of Cerus Corporation stock is 19.88%, while year-to-date (YTD) performance is -12.28%. CERS stock has a five-year performance of -2.41%. Its 52-week range is between 4.87 and 8.87, which gives CERS stock a 52-week price range ratio of 34.25%

Cerus Corporation currently has a PE ratio of -16.90, a price-to-book (PB) ratio of 9.84, a price-to-sale (PS) ratio of 11.51, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -29.81%, a ROC of -40.03% and a ROE of -72.15%. The company’s profit margin is -47.86%, its EBITDA margin is -46.10%, and its revenue ttm is $89.61 Million , which makes it $0.53 revenue per share.

Of the last four earnings reports from Cerus Corporation, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. Cerus Corporation’s next earnings report date is 04th May 2021.

The consensus rating of Wall Street analysts for Cerus Corporation is Strong Buy (1), with a target price of $9.1, which is +47.25% compared to the current price. The earnings rating for Cerus Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cerus Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cerus Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.75, ATR14 : 0.55, CCI20 : -0.46, Chaikin Money Flow : 0.08, MACD : -0.33, Money Flow Index : 46.90, ROC : 4.12, RSI : 41.64, STOCH (14,3) : 61.62, STOCH RSI : 0.93, UO : 44.77, Williams %R : -38.38), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cerus Corporation in the last 12-months were: Carol M. Moore (Option Excercise at a value of $450 457), Carol M. Moore (Sold 181 646 shares of value $1 253 915 ), Chrystal Menard (Option Excercise at a value of $1 141 904), Chrystal Menard (Sold 304 787 shares of value $2 368 738 ), Daniel N. Swisher (Option Excercise at a value of $58 000), Daniel N. Swisher (Sold 20 000 shares of value $140 302 ), Eric H. Bjerkholt (Option Excercise at a value of $0), Gail Gaumer Schulze (Option Excercise at a value of $37 200), Gail Gaumer Schulze (Sold 62 393 shares of value $456 817 ), Jami Dover Nachtsheim (Option Excercise at a value of $0), Kevin D. Green (Option Excercise at a value of $166 400), Kevin D. Green (Sold 101 513 shares of value $658 540 ), Laurence M. Corash (Option Excercise at a value of $346 968), Richard J. Benjamin (Option Excercise at a value of $1 180 028), Richard J. Benjamin (Sold 254 583 shares of value $1 903 044 ), Timothy B. Anderson (Option Excercise at a value of $655 958), Timothy B. Anderson (Sold 135 496 shares of value $1 023 622 ), Timothy L. Moore (Option Excercise at a value of $0), Vivek K. Jayaraman (Option Excercise at a value of $406 031), Vivek K. Jayaraman (Sold 143 895 shares of value $1 151 160 ), William M. Greenman (Option Excercise at a value of $300 000), Witney Frank (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
4 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cerus Corporation

Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East and selected countries in other regions around the world. The firm continues to operate in only one segment: blood safety and generates revenue from the same.

CEO: William M. Greenman

Telephone: +1 925 288-6000

Address: 1220 Concord Avenue, Concord 94520, CA, US

Number of employees: 270

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

56%44%

Bearish Bullish

54%46%

Bearish Bullish

60%40%

News

Stocktwits